Format

Send to

Choose Destination
Oncotarget. 2015 Nov 10;6(35):37229-40. doi: 10.18632/oncotarget.5954.

Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.

Author information

1
Laboratory of Molecular Pharmacology and Laboratory of Cancer Pharmacology, Department of Oncology, IRCCS- Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.
2
Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland.
3
Dalle Molle Institute for Artificial Intelligence (IDSIA), Manno, Switzerland.
4
Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
5
Lymphoma Unit, IOSI Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.

Abstract

Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma characterized by the chromosomal translocation t(11;14) that leads to constitutive expression of cyclin D1, a master regulator of the G1-S phase. Chk1 inhibitors have been recently shown to be strongly effective as single agents in MCL. To investigate molecular mechanisms at the basis of Chk1 inhibitor activity, a MCL cell line resistant to the Chk1 inhibitor PF-00477736 (JEKO-1 R) was obtained and characterized. The JEKO-1 R cell line was cross resistant to another Chk1 inhibitor (AZD-7762) and to the Wee1 inhibitor MK-1775. It displayed a shorter doubling time than parental cell line, likely due to a faster S phase. Cyclin D1 expression levels were decreased in resistant cell line and its re-overexpression partially re-established PF-00477736 sensitivity. Gene expression profiling showed an enrichment in gene sets involved in pro-survival pathways in JEKO-1 R. Dasatinib treatment partly restored PF-00477736 sensitivity in resistant cells suggesting that the pharmacological interference of pro-survival pathways can overcome the resistance to Chk1 inhibitors. These data further corroborate the involvement of the t(11;14) in cellular sensitivity to Chk1 inhibitors, fostering the clinical testing of Chk1 inhibitors as single agents in MCL.

KEYWORDS:

Chk1; cyclin D1; mantle cell lymphoma; mechanisms of resistance; targeted therapy

PMID:
26439697
PMCID:
PMC4741926
DOI:
10.18632/oncotarget.5954
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center